Rigel Pharmaceuticals, Inc.RIGLNASDAQ
Loading
Year-over-year operating income growth rate
Percentile
P41
Within normal range
vs 3Y Ago
-0.2x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | -18.47% |
| Q3 2025 | -53.49% |
| Q2 2025 | 378.38% |
| Q1 2025 | -23.31% |
| Q4 2024 | 18.49% |
| Q3 2024 | 3044.52% |
| Q2 2024 | 106.42% |
| Q1 2024 | -454.32% |
| Q4 2023 | 144.03% |
| Q3 2023 | 15.23% |
| Q2 2023 | 58.61% |
| Q1 2023 | -712.07% |
| Q4 2022 | 111.30% |
| Q3 2022 | -41.94% |
| Q2 2022 | 50.63% |
| Q1 2022 | -22.61% |
| Q4 2021 | -8.25% |
| Q3 2021 | -51.63% |
| Q2 2021 | -131.25% |
| Q1 2021 | 321.78% |
| Q4 2020 | -36.62% |
| Q3 2020 | 20.76% |
| Q2 2020 | -182.71% |
| Q1 2020 | 221.28% |
| Q4 2019 | -44.03% |
| Q3 2019 | 43.59% |
| Q2 2019 | -16.11% |
| Q1 2019 | -825.83% |
| Q4 2018 | 110.39% |
| Q3 2018 | 6.67% |
| Q2 2018 | -5.57% |
| Q1 2018 | 5.65% |
| Q4 2017 | -46.82% |
| Q3 2017 | 7.70% |
| Q2 2017 | -19.39% |
| Q1 2017 | -2.63% |
| Q4 2016 | 30.57% |
| Q3 2016 | -66.61% |
| Q2 2016 | 22.31% |
| Q1 2016 | -37.81% |